HRP20120687T1 - Moduliranje metabolizma prostaglandina/ciklooksigenaze - Google Patents
Moduliranje metabolizma prostaglandina/ciklooksigenaze Download PDFInfo
- Publication number
- HRP20120687T1 HRP20120687T1 HRP20120687TT HRP20120687T HRP20120687T1 HR P20120687 T1 HRP20120687 T1 HR P20120687T1 HR P20120687T T HRP20120687T T HR P20120687TT HR P20120687 T HRP20120687 T HR P20120687T HR P20120687 T1 HRP20120687 T1 HR P20120687T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- compound
- hydrogen atom
- use according
- prophylaxis
- Prior art date
Links
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 title 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 title 1
- 230000037353 metabolic pathway Effects 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 210000002345 respiratory system Anatomy 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims abstract 3
- 125000002252 acyl group Chemical group 0.000 claims abstract 2
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- RNCGWYKXAJCOLD-JUKXBMAYSA-N 7alpha -hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](O)CC2=C1 RNCGWYKXAJCOLD-JUKXBMAYSA-N 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
Abstract
Upotreba spoja formule (II): u kojoj: R1 predstavlja atom vodika ili metilnu skupinu; iR2, R3 i R4 su isti ili su međusobno različiti, a svaki od njih predstavlja okso skupinu, hidroksi skupinu, merkapto skupinu, atom vodika, atom halogena, alkoksi skupinu, ariloksi skupinu ili acilnu skupinu; ili njegove farmaceutski prihvatljive soli ili estera, naznačena time ®to je navedeni spoj namijenjen proizvodnji medikamenta za liječenje ili profilaksu upalnih bolesti di®nih puteva. Patent sadr·i jo® 3 patentna zahtjeva.
Claims (4)
1. Upotreba spoja formule (II):
[image]
u kojoj:
R1 predstavlja atom vodika ili metilnu skupinu; i
R2, R3 i R4 su isti ili su međusobno različiti, a svaki od njih predstavlja okso skupinu, hidroksi skupinu, merkapto skupinu, atom vodika, atom halogena, alkoksi skupinu, ariloksi skupinu ili acilnu skupinu;
ili njegove farmaceutski prihvatljive soli ili estera,
naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje ili profilaksu upalnih bolesti dišnih puteva.
2. Upotreba u skladu s patentnim zahtjevom 1, naznačena time što upalna bolest dišnih puteva uključuje astmu, rinitis, bronhitis ili kroničnu opstruktivnu plućnu bolest.
3. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je namijenjena liječenju i profilaksi: astme i kronične opstruktivne plućne bolesto.
4. Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj formule (II) 7-hidroksitestosteron.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86787306P | 2006-11-30 | 2006-11-30 | |
| GB0623971A GB0623971D0 (en) | 2006-11-30 | 2006-11-30 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| PCT/GB2007/004584 WO2008065408A2 (en) | 2006-11-30 | 2007-11-29 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120687T1 true HRP20120687T1 (hr) | 2012-09-30 |
Family
ID=39381924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120687TT HRP20120687T1 (hr) | 2006-11-30 | 2012-08-29 | Moduliranje metabolizma prostaglandina/ciklooksigenaze |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100137270A1 (hr) |
| EP (2) | EP2147673A1 (hr) |
| JP (1) | JP2010511028A (hr) |
| KR (1) | KR20090086272A (hr) |
| AU (1) | AU2007327011A1 (hr) |
| CA (1) | CA2670957A1 (hr) |
| HR (1) | HRP20120687T1 (hr) |
| IL (1) | IL199013A0 (hr) |
| MX (1) | MX2009005753A (hr) |
| NO (1) | NO20092455L (hr) |
| PL (1) | PL2097079T3 (hr) |
| TW (1) | TWI414298B (hr) |
| WO (1) | WO2008065408A2 (hr) |
| ZA (1) | ZA200903584B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| WO2013120851A1 (en) * | 2012-02-13 | 2013-08-22 | Mach-3D Sàrl | Method for sharing emotions through the creation of three-dimensional avatars and their interaction through a cloud-based platform |
| US9328060B2 (en) | 2013-10-18 | 2016-05-03 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics |
| WO2017141968A1 (ja) * | 2016-02-15 | 2017-08-24 | 学校法人近畿大学 | 抗不安作用を有する医薬組成物および加工食品 |
| WO2023060107A1 (en) * | 2021-10-05 | 2023-04-13 | University Of South Florida | Compositions and uses thereof for treatment of neurological disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7100213A (en) * | 1971-01-08 | 1972-07-11 | 1,2,3,4-tetrahydrocarbazole derivs - anti-inflammatories | |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5451600A (en) * | 1994-04-19 | 1995-09-19 | Hoffmann-La Roche Inc. | Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors |
| CN1116870C (zh) * | 1996-03-15 | 2003-08-06 | 萨默塞特药品有限公司 | 司立吉林在制备用于预防或治疗外周神经病的药物中的应用 |
| AU4229499A (en) * | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| GB0003524D0 (en) * | 2000-02-15 | 2000-04-05 | Btg Int Ltd | Cytoprotective steroids (II) |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| WO2002015791A2 (en) | 2000-08-25 | 2002-02-28 | Michael John Till | Sampling device |
| EP2135611A1 (en) * | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
| SE0100857D0 (sv) * | 2001-03-13 | 2001-03-13 | Tomas Hagstroem | Treatment of tumors |
| GB2378898A (en) | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
| FR2829697B1 (fr) * | 2001-09-14 | 2004-03-19 | Mayoly Spindler Lab | Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin |
| GB0403889D0 (en) * | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| US20060234993A1 (en) * | 2005-04-13 | 2006-10-19 | Eric Marchewitz | Use of androstane derivatives for enhancing physical performance |
-
2007
- 2007-11-29 AU AU2007327011A patent/AU2007327011A1/en not_active Abandoned
- 2007-11-29 US US12/516,772 patent/US20100137270A1/en not_active Abandoned
- 2007-11-29 PL PL07870407T patent/PL2097079T3/pl unknown
- 2007-11-29 EP EP09012181A patent/EP2147673A1/en not_active Withdrawn
- 2007-11-29 JP JP2009538785A patent/JP2010511028A/ja active Pending
- 2007-11-29 WO PCT/GB2007/004584 patent/WO2008065408A2/en active Application Filing
- 2007-11-29 KR KR1020097013708A patent/KR20090086272A/ko not_active Application Discontinuation
- 2007-11-29 CA CA002670957A patent/CA2670957A1/en not_active Abandoned
- 2007-11-29 MX MX2009005753A patent/MX2009005753A/es active IP Right Grant
- 2007-11-29 EP EP07870407A patent/EP2097079B1/en active Active
- 2007-11-30 TW TW096145663A patent/TWI414298B/zh not_active IP Right Cessation
-
2009
- 2009-05-22 ZA ZA2009/03584A patent/ZA200903584B/en unknown
- 2009-05-27 IL IL199013A patent/IL199013A0/en unknown
- 2009-06-29 NO NO20092455A patent/NO20092455L/no not_active Application Discontinuation
-
2012
- 2012-08-03 US US13/566,136 patent/US20130023504A1/en not_active Abandoned
- 2012-08-29 HR HRP20120687TT patent/HRP20120687T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008065408A2 (en) | 2008-06-05 |
| AU2007327011A1 (en) | 2008-06-05 |
| IL199013A0 (en) | 2010-02-17 |
| EP2097079A2 (en) | 2009-09-09 |
| TW200831108A (en) | 2008-08-01 |
| US20130023504A1 (en) | 2013-01-24 |
| ZA200903584B (en) | 2010-11-24 |
| US20100137270A1 (en) | 2010-06-03 |
| WO2008065408A3 (en) | 2008-11-20 |
| WO2008065408A9 (en) | 2011-03-03 |
| MX2009005753A (es) | 2009-09-28 |
| CA2670957A1 (en) | 2008-06-05 |
| EP2147673A1 (en) | 2010-01-27 |
| KR20090086272A (ko) | 2009-08-11 |
| JP2010511028A (ja) | 2010-04-08 |
| EP2097079B1 (en) | 2012-06-27 |
| TWI414298B (zh) | 2013-11-11 |
| NO20092455L (no) | 2009-08-14 |
| PL2097079T3 (pl) | 2012-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120687T1 (hr) | Moduliranje metabolizma prostaglandina/ciklooksigenaze | |
| HRP20150938T1 (hr) | Derivati purina namijenjeni upotrebi u lijeäśenju alergijskih, upalnih i zaraznih bolesti | |
| MY154895A (en) | Pyrimidine hydrazide compounds as pgds inhibitors | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| RS52661B (en) | THERAPEUTIC MEANS | |
| PE20151651A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| MX2009004289A (es) | Compuestos triciclicos como inhibidores de metaloproteinasas matriciales. | |
| RS53080B (en) | AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT | |
| IL198226A0 (en) | 2-[l-phenyl-5-hydroxy-4alpha-methyl | |
| NZ566788A (en) | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | |
| NZ602191A (en) | Heterocyclic amides as rock inhibitors | |
| NO20091560L (no) | Biaryleterureaforbindelser | |
| TW200736221A (en) | Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor | |
| HRP20100020T1 (hr) | Novi derivati hidantoina za liječenje opstruktivnih bolesti dišnih putova | |
| TR201904655T4 (tr) | Piridilaminoasetik asit bileşiği. | |
| WO2008137816A8 (en) | Tricyclic compounds as matrix metalloproteinase inhibitors | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| DE602007009839D1 (de) | Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| MX2008010884A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1. | |
| NO20084516L (no) | Terfenylderivater for behandling av alzheimers sykdom | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| BR112013000065A2 (pt) | compostos atuantes nos múltplos receptores de prostaglandina que fornecem uma resposta anti-flamatória geral | |
| NZ599099A (en) | Phenyloxadiazole derivatives as pgds inhibitors | |
| BR112013027486A2 (pt) | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor |